Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Ovarian Cancer Clinical Trials

115 recruiting trials for Ovarian Cancer. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
115
Total Trials
115
Recruiting Now
3
Phase 3 Trials
10
Sponsors

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1NCT06999187

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or...

Sponsor: Dren BioEnrolling: 9610 locations
RECRUITINGNCT03702309

Liquid Biopsy Evaluation and Repository Development at Princess Margaret

The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor...

Sponsor: University Health Network, TorontoEnrolling: 25001 location
RECRUITINGPhase 1NCT06617169

Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors

This is an open-label, uncontrolled, multi-center, phase 1a MNPR-101-PCTA-177Lu dose-escalation study in patients with solid tumor cancers. Patients must have participated in the...

Sponsor: Monopar TherapeuticsEnrolling: 121 location
RECRUITINGPhase 1NCT06774963

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended...

Sponsor: NextCure, Inc.Enrolling: 14514 locations
RECRUITINGPhase 1NCT06293898

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

Sponsor: SystImmune Inc.Enrolling: 28017 locations
RECRUITINGNCT07124000

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior...

Sponsor: AstraZenecaEnrolling: 10017 locations
RECRUITINGPhase 1NCT07444814

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With...

HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in...

Sponsor: Whitehawk Therapeutics, Inc.Enrolling: 22612 locations
RECRUITINGPhase 2NCT05489211

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours...

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer...

Sponsor: AstraZenecaEnrolling: 45420 locations
RECRUITINGPhase 1 / Phase 2NCT06926075

Early Phase Study of KESONOTIDE™in Participants With Solid Tumours

This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers. It is an open label, multicentre, single ascending dose level in phase I and cohort exploration...

Sponsor: Filamon LTDEnrolling: 803 locations
RECRUITINGPhase 1 / Phase 2NCT06799637

Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments

This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor...

Sponsor: Evopoint Biosciences Inc.Enrolling: 35020 locations
RECRUITINGPhase 2 / Phase 3NCT06896981

Semaglutide in Women With Polycystic Ovary Syndrome and Obesity

Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder that is frequently associated with metabolic features, including obesity. Improvement of metabolic manifestations...

Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshEnrolling: 301 location
RECRUITINGPhase 2NCT06141265

Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab

This study is a multicenter, open-label, single-arm phase II clinical trial investigating the efficacy and safety of niraparib monotherapy maintenance in HRD-positive newly...

Sponsor: Peking University Cancer Hospital & InstituteEnrolling: 1161 location
RECRUITINGPhase 1NCT06010875

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive...

Sponsor: Chongqing Precision Biotech Co., LtdEnrolling: 481 location
RECRUITINGNCT07169396

Identifying Genetic Targets in Gynecological Tumors

This observational study aims to identfy genetic targets involved in the pathogenesis of gynecological tumors, with a focus on high-grade serous ovarian carcinoma. Using a triple...

Sponsor: Azienda USL Reggio Emilia - IRCCSEnrolling: 1801 location
RECRUITINGPhase 1NCT07402915

Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or...

The purpose of this study is to assess the effect of itraconazole on the pharmacokinetics (PK) of AZ14170132.

Sponsor: AstraZenecaEnrolling: 249 locations
RECRUITINGPhase 3NCT05827523

Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)

Primary stage III-IV epithelial ovarian cancer randomizing between interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC)

Sponsor: National Cancer Center, KoreaEnrolling: 52010 locations
RECRUITINGNCT06019923

Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer

Ovarian cancer is a highly lethal gynecological malignancy, often diagnosed at an advanced stage, with high rates of recurrence within 1-2 years after frontline treatment. Current...

Sponsor: Women's Hospital School Of Medicine Zhejiang UniversityEnrolling: 1001 location
RECRUITINGPhase 2NCT05704621

Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor...

This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance.

Sponsor: Korea University Guro HospitalEnrolling: 1241 location
RECRUITINGPhase 1 / Phase 2NCT05941507

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1)...

Sponsor: LigaChem Biosciences, Inc.Enrolling: 3008 locations
RECRUITINGPhase 1NCT06321484

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

The goal of this research study is to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy in recurrent, high...

Sponsor: Dana-Farber Cancer InstituteEnrolling: 182 locations
RECRUITINGPhase 1 / Phase 2NCT06128551

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C...

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated...

Sponsor: Revolution Medicines, Inc.Enrolling: 53420 locations
RECRUITINGNCT05206890

A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer

Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors,...

Sponsor: Tongji HospitalEnrolling: 4901 location
RECRUITINGPhase 2NCT06686030

Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

An Exploratory, Multi-cohort Phase II Study of combination therapy of AK112 with chemotherapy and/or olaparib in platinum-sensitive ovarian cancer(PSOC)

Sponsor: AkesoEnrolling: 1501 location
RECRUITINGNCT05984875

The Immune Landscape of Epithelial Ovarian Cancer

This is a single center prospective observational study to characterize the immune landscape of newly diagnosed epithelial ovarian cancer (OC). Patients with newly diagnosed...

Sponsor: Oncology Institute of Southern SwitzerlandEnrolling: 741 location
RECRUITINGPhase 2NCT05974449

Lactobacillus Vaginalis Capsules for Treatment of Vulvovaginal Atrophy in Young Breast Cancer Patients

This study is a prospective, randomized controlled, phase II clinical study with a planned enrolment of 60 patients. The study focuses on the efficacy and safety of Lactobacillus...

Sponsor: The First Affiliated Hospital with Nanjing Medical UniversityEnrolling: 601 location
RECRUITINGPhase 1NCT06642363

The Effectiveness of Astaxanthin Supplementation on the Clinical Symptoms and Cardio-metabolic Profile in Women with...

Abstract Background: This trial aims to investigate the effect of 12 weeks of 10 mg/day astaxanthin (ASX) administration compared with the control group on insulin sensitivity,...

Sponsor: Isfahan University of Medical SciencesEnrolling: 441 location
RECRUITINGNCT05721976

With Love, Grandma ("Con Cariño, Abuelita") Pilot Study

The purpose of this study is to assess the feasibility, acceptability, and preliminary effects of a digital (web and mobile-phone-based) program to improve lifestyle behaviors...

Sponsor: University of Miami Sylvester Comprehensive Cancer CenterEnrolling: 601 location
RECRUITINGPhase 1NCT06515613

A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific...

Sponsor: Context Therapeutics Inc.Enrolling: 8013 locations
RECRUITINGPhase 2NCT05983276

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

The goal of this clinical trial is to learn about the side effects and effectiveness of this novel four-drug combination of chemotherapy (decitabine, selinexor, carboplatin and...

Sponsor: Loyola UniversityEnrolling: 401 location
RECRUITINGNCT05743517

Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)

The primary purpose of the study is to determine which of four components (symptom-burden tailored app, exercise partner, oncology provider engagement, coaching) added to a core...

Sponsor: Northwestern UniversityEnrolling: 1921 location
RECRUITINGPhase 1NCT07213791

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called...

Sponsor: Eli Lilly and CompanyEnrolling: 24120 locations
RECRUITINGPhase 2 / Phase 3NCT07219238

Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With...

This study is a Phase 2/3, prospective, multicenter, open-label, non-randomized clinical trial, in which GEH300079 (68Ga) PET/CT images will be acquired in patients with primary...

Sponsor: GE HealthcareEnrolling: 1752 locations
RECRUITINGNCT06793098

Functional Proteins in Polycystic Ovary Syndrome

The concentration of functional proteins: kisspeptin, ghrelin, zonulin will be measured and compared in women with polycystic ovary syndrome (PCOS) and insulin resistance (IR), in...

Sponsor: Jagiellonian UniversityEnrolling: 1001 location
RECRUITINGPhase 2NCT05128825

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary...

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or...

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncEnrolling: 31020 locations
RECRUITINGPhase 2NCT06971744

Autophagy Maintenance (AUTOMAIN)

This is a single-institution, single-arm study with a safety lead-in to determine if previously established safe doses of autophagy drugs, hydroxychloroquine (HCQ) and nelfinavir...

Sponsor: Medical University of South CarolinaEnrolling: 381 location
RECRUITINGPhase 1 / Phase 2NCT05211557

Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer

This is single center, open-label phase I, non-randomized study which will enroll patients with recurrent advanced ovarian cancer to evaluate the safety, feasibility, and efficacy...

Sponsor: The Affiliated Hospital of Xuzhou Medical UniversityEnrolling: 151 location
RECRUITINGPhase 2NCT04644289

WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC

This is a multi-center, prospective, open-label, phase II trial. Patients with suspected advanced ovarian cancer planned to undergo diagnostic laparoscopy for histologic...

Sponsor: AGO Research GmbHEnrolling: 606 locations
RECRUITINGPhase 2NCT07229040

A Double-blind Non Inferiority Clinical Trial to Compare the Nephroprotection of Cilastatn Versus Thiosulfate in...

To compare cilastatin vs thiosulfatein renal protection in patients undergoing debulking surgery with intraoperative hyperthermic intraperitoneal chemotherapy with cisplatin

Sponsor: Hospital General Universitario Gregorio MarañonEnrolling: 901 location
RECRUITINGNCT04665635

Rectosigmoid Resection vs Seromuscular Tumor Shaving in Ovarian Cancer Surgery

Ovarian cancer is the most common cause of death in gynecological cancer. Approximately 75% of epithelial ovarian cancers are detected at an advanced stage. Metastasis and spread...

Sponsor: Cukurova UniversityEnrolling: 1202 locations
RECRUITINGPhase 2NCT06315491

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125...

Sponsor: Cybrexa TherapeuticsEnrolling: 4017 locations
RECRUITINGPhase 1 / Phase 2NCT07488676

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid...

Sponsor: Astellas Pharma Global Development, Inc.Enrolling: 1508 locations
RECRUITINGPhase 1NCT05942300

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

This is a clinical trial using CPI-0209 in combination with Carboplatin chemotherapy followed by CPI-0209 maintenance in patients with platinum sensitive, recurrent ovarian cancer.

Sponsor: Lan CoffmanEnrolling: 301 location
RECRUITINGPhase 2 / Phase 3NCT06341907

Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC

The goal of this clinical trial is as follows:(1) Establish a clinical technical system for ctDNA dynamic monitoring of MRD in postoperative EOC patients, providing a new...

Sponsor: Second Affiliated Hospital of Wenzhou Medical UniversityEnrolling: 101 location
RECRUITINGNCT07142603

Appetite Response to Meals With Different Protein Sources in Women With PCOS

Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by insulin resistance, hyperandrogenism, and reproductive dysfunction. Dietary strategies that...

Sponsor: University of Arkansas, FayettevilleEnrolling: 301 location
RECRUITINGNCT01970696

International Ovarian & Testicular Stromal Tumor Registry

Rare tumors are understudied, yet have the potential to shed light on vast areas of cancer research. Ovarian sex cord-stromal tumors, rare tumors of childhood and young adulthood,...

Sponsor: Children's Hospitals and Clinics of MinnesotaEnrolling: 3001 location
RECRUITINGPhase 2NCT03275194

HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy

Ovarian cancer is the leading cause of gynecological cancer mortality, with no current screening method effective for early diagnosis, with 75% of advanced stage patients being...

Sponsor: Instituto Nacional de Cancerologia de MexicoEnrolling: 1001 location
RECRUITINGNCT07469709

A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks

The PRO-ACTIVE study aims to develop a clinical-translational program in the field of cancer prevention in all its phases (primary, secondary, and tertiary) to intervene before...

Sponsor: Fondazione del Piemonte per l'OncologiaEnrolling: 8501 location
RECRUITINGPhase 2NCT06330064

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic...

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell...

Sponsor: Daiichi SankyoEnrolling: 52020 locations
RECRUITINGPhase 4NCT05606692

Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)

Ⅶ. Study procedures (summary) 1. Written informed consent must be obtained before any study specific procedures are undertaken. Qualified participants were identified at the...

Sponsor: Kaohsiung Medical University Chung-Ho Memorial HospitalEnrolling: 4161 location
RECRUITINGNCT07289399

Is There a Benefit From Addition of Treadmill Walking to Diet Restriction in Psoriasis Women With PCOS?

Women with psoriasis usually develop many complications including polysyctic ovarian syndrome (PCOS). Nowdays, diet restriction combimed with phsyical exercises may improve both...

Sponsor: Cairo UniversityEnrolling: 401 location

Showing 50 of 115 trials.Search all Ovarian Cancer trials

Frequently Asked Questions

There are currently 115 clinical trials for Ovarian Cancer, with 115 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Ovarian Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 3 Phase 3 trials for Ovarian Cancer, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.

The this entity record above pulls directly from the NIH ClinicalTrials.gov registry. What follows is the per-entity context — how this entity sits in the broader U.S. clinical trials and research registries distribution and which underlying factors drive the headline numbers.

The methodology behind every numeric value on this page is publicly documented on the the NIH ClinicalTrials.gov registry portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for this entity is typically a peer within active and historical clinical trials with similar size, similar exposure, or similar geography — not the national-level summary alone.